Many noncancerous pediatric blood disorders can threaten your child’s health or life, and Miami Cancer Institute’s hematology/oncology team is highly experienced in their diagnosis and treatment. We understand a child’s blood disorder can dramatically change your life and affect your family, and we’re here for you. We’ll make sure you and your family understand your child’s condition and how to help your child stay as healthy and active as possible, and offer support and resources to help you and your family adjust and cope. As Florida’s only member of the Memorial Sloan Kettering Alliance, we’re committed to improving treatment and management of pediatric blood disorders and may be able to offer treatment methods that are not widely available elsewhere in the region.
Pediatric blood disorders include a wide range of diseases and disorders that are most commonly diagnosed in childhood. These disorders can affect any component of the blood, including red or white blood cells, platelets, lymph nodes or blood vessels. Some are life-threatening; others may have few symptoms and cause few problems.
Some pediatric blood disorders commonly treated at Miami Cancer Institute include:
Rarer blood conditions are also be treated at Miami Cancer Institute, and we can also draw from the resources of the Memorial Sloan Kettering Cancer Alliance to offer complete, multidisciplinary care and management.
Risk factors vary by disorder.
Sickle cell disease is most common in certain ethnic groups, including:
Anemia risk factors can include:
Bleeding disorders are most commonly inherited.
Some forms of anemia can be prevented with a healthy and balanced diet or with doctor-recommended supplements. But most blood disorders can not be prevented. You can take steps to help prevent complications, and our team will work closely with you to make sure you know how to best care for your child.
Some blood disorders can be detected by screening.
Screening for sickle cell disease involves a blood test that checks for hemoglobin S, a defective form of hemoglobin. In the United States, this blood test is part of routine newborn screening.
Screening for anemia involves a blood test and is recommended by the American Academy of Pediatrics (AAP) between the ages of 9 to 12 months, with additional screening between the ages of 1 and 5 years for children at risk.